Clinical grade development of an Ai system for diagnosis and Gleason grading of prostate cancer.

Important results from the project

Together with Karolinska Institutet and Karolinska Universitetssjukhuset, Clinsight has built an AI system as an aid to pathologists to diagnose and Gleason-grade prostate cancer from digitized histopathological sections with better precision and concordance. The system has been validated retrospectively on a large clinical cohort from 13 different clinical institutions in Europe and shows excellent clinical precision. The AI system, named ClinAI is available as an Research Use Only (RUO) and is integrated with Sectra and Mindpeak´s image processing system.

Expected long term effects

** Denna text är maskinöversatt ** The Clinsights AI System for Diagnosing and Gleason Grading Prostate Cancer is a tool for pathologists to use to increase the precision and efficiency of prostate cancer diagnosis by automatically analyzing digitized histopathological sections. The system shows regions that contain cancer, assesses the Gleason grade of these cases and how much of the sample contains cancer for evaluation by pathologists. It is estimated that this will increase diagnostic certainty, reproducibility in pathology and the quality of diagnostics in a scalable way.

Approach and implementation

Clinsight has coordinated this project with Karolinska Institutet and Karolinska Universitetssjukhuset. The Ai system has been developed and validated by Professor Eklund and Dr Kartasalo. Professor Egevad from Karolinska Universitetssjukhuset has evaluated and annotated digitized histopathological sections for training the Ai system. Clinsight has built the integration of the AI system into two clinical systems and managed collaborations with experts in Medtech and preparation for the CEIVDR proposal and was responsible for integration, IP and regulatory preparation.